11
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Platforms and Artificial Intelligence in Dementia

      Submit here by August 31, 2025

      About Dementia and Geriatric Cognitive Disorders: 2.2 Impact Factor I 4.7 CiteScore I 0.809 Scimago Journal & Country Rank (SJR)

      Call for Papers: Skin Health in Aging Populations

      Submit here by August 31, 2025

      About Skin Pharmacology and Physiology: 2.8 Impact Factor I 5.2 CiteScore I 0.623 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Alitretinoin as a Treatment Modality for Ichthyosis in Women of Childbearing Age: A Case Series and Review of the Literature

      brief-report

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Acitretin, a synthetic vitamin A derivative, is the most studied and widely used oral retinoid for ichthyoses. Its major disadvantage is the need for contraceptive measures during 3 years after discontinuation. An alternative is needed for women of childbearing age. With alitretinoin, another retinoid, pregnancy is considered safe 1 month after discontinuation. Objectives: The aim of this study was to provide evidence for alitretinoin as an alternative for acitretin for ichthyosis in women of childbearing age. Our experience is shared in a case series combined with an overview of the current literature. Methods: Nine women of childbearing age (19–31 years, median 21) with different subtypes of ichthyosis (autosomal recessive congenital ichthyosis, (superficial) epidermolytic ichthyosis, erythrokeratoderma variabilis, and epidermolytic epidermal nevi, a mosaic form of epidermolytic ichthyosis) were included and treated with 30 mg alitretinoin during 2–28 months. Severity was measured by Ichthyosis Area Severity Index (IASI) and Investigator Global Assessment (IGA). A literature search in Pubmed using the Mesh terms “alitretinoin,” “skin diseases, genetic” and “ichthyosis” was performed. Results: Significant reduction in the mean scores of IGA, IASI-erythema, IASI-scaling, and IASI-total was seen. Seven patients are still being treated, 1 patient stopped to become pregnant, 1 patient discontinued due to financial reasons. Observed side effects were reversible headache ( n = 6), asteatotic eczema ( n = 1), “not feeling well” temporarily ( n = 1), and easier blistering of the feet ( n = 1). The literature search resulted in six case reports and case series about alitretinoin in ichthyosis and ichthyosis syndromes with in total 29 patients. The vast majority of articles (21/29) reported significant improvement or even complete remission of skin symptoms. However, validated outcome measures to support these results were lacking. Side effects ( n = 16) were relatively mild, except for benign intracranial hypertension ( n = 1) and autoimmune hypothyroidism ( n = 1). Conclusion: Our study shows, with validated outcome measures, that alitretinoin is effective to mitigate the symptoms of ichthyosis in women of childbearing age and a suitable alternative to acitretin.

          Related collections

          Author and article information

          Journal
          DRM
          Dermatology
          10.1159/issn.1018-8665
          Dermatology
          Dermatology
          S. Karger AG
          1018-8665
          1421-9832
          2024
          February 2024
          04 September 2023
          : 240
          : 1
          : 170-177
          Affiliations
          [_a] aDepartment of Dermatology, Maastricht University Medical Centre +, Maastricht, The Netherlands
          [_b] bGROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
          [_c] cDepartment of Dermatology, Haga Hospital, The Hague, The Netherlands
          [_d] dDepartment of Dermatology, Meander Medical Centre, Amersfoort, The Netherlands
          [_e] eDepartment of Dermatology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
          [_f] fDepartment of Clinical Genetics, Maastricht University Medical Centre +, Maastricht, The Netherlands
          Author notes
          *Antoni Gostynski, antoni.gostynski@mumc.nl
          Article
          533934 Dermatology 2024;240:170–177
          10.1159/000533934
          37666225
          4ceb021b-ebaa-4c4b-8b90-33139d59988e
          © 2023 The Author(s). Published by S. Karger AG, Basel

          This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.

          History
          : 29 March 2023
          : 31 August 2023
          Page count
          Figures: 2, Tables: 3, Pages: 8
          Funding
          The authors did not receive funding from any organization for this study.
          Categories
          Brief Report

          Medicine
          Genodermatoses,Ichthyosis,Alitretinoin
          Medicine
          Genodermatoses, Ichthyosis, Alitretinoin

          Comments

          Comment on this article

          Related Documents Log